To the Editor We read with great interest the randomized clinical trial by Csonka et al, which provides compelling evidence that valved holding chambers (VHCs) are not clinically interchangeable in managing acute wheezing in young children. Their findings demonstrate that a high-delivery device (VHC-1; OptiChamber Diamond) led to significantly lower posttreatment respiratory distress assessment instrument scores (2.7 vs 6.8) and a 30% absolute reduction in hospitalization rates (20% vs 50%) compared to a low-delivery device (VHC-2; Babyhaler). These outcomes are supported by in vitro data showing a 23-fold difference in salbutamol delivery under simulated pediatric respiratory distress.